Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FoxHollow Finds Rinspiration For Cardiac Market Entry Via Kerberos Purchase

This article was originally published in The Gray Sheet

Executive Summary

FoxHollow's acquisition of the Rinspiration thrombectomy device through its $32 mil. purchase of Kerberos Proximal Solutions provides the firm with immediate access to the coronary market

You may also be interested in...



Bayer Builds Cardiovascular Franchise With Possis Purchase

Bayer HealthCare will expand its cardiovascular device offerings by acquiring AngioJet thrombectomy system maker Possis Medical for $361 million under a deal announced Feb. 11

Bayer Builds Cardiovascular Franchise With Possis Purchase

Bayer HealthCare will expand its cardiovascular device offerings by acquiring AngioJet thrombectomy system maker Possis Medical for $361 million under a deal announced Feb. 11

FoxHollow Stock Up 25% In Q3 On SilverHawk Profitability, Merck Deal

FoxHollow's stock advanced 25.1% in the third quarter as investors took notice of the firm's first profitable quarter, increased adoption of the company's SilverHawk peripheral vessel plaque excision system and an expanded research agreement with Merck

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel